文献速递治疗药物监测与药物基因组学

是否应放弃他克莫司全血治疗药物监测而转向细胞内浓度测定?

Should we abandon therapeutic drug monitoring of tacrolimus in whole blood and move to intracellular concentration measurements?
PubMed 文献 · Br J Clin Pharmacol · 2023-11-22

本文综述讨论他克莫司全血浓度监测的局限:全血中>99%的他克莫司与红细胞和血浆蛋白结合,为无药理活性部分,而游离及细胞内他克莫司仅占全血浓度1%或更少。作者认为细胞内他克莫司浓度可能更好反映药效并与临床结局相关,但现有研究结果矛盾,需先克服细胞内浓度测定的分析局限性再进入临床。

要点

  • 全血他克莫司>99%与红细胞和血浆蛋白结合,无药理活性。
  • 游离及细胞内他克莫司仅占全血浓度1%或更少,为活性部分。
  • 细胞内他克莫司浓度测定研究结果矛盾,需先解决分析局限。

核心结论

  • 在将细胞内他克莫司浓度测定技术推向临床前,需先克服现有检测方法的分析局限性。
  • 细胞分离过程的有效性与标准化对细胞内他克莫司浓度测定同样重要,但关注不足。
  • 近期证据提示,加入P-糖蛋白抑制剂可防止细胞分离过程中他克莫司被排出。

研究设计与样本

  • 本文为综述,检索范围未在摘要中报告。

主要发现

  • 全血中>99%的他克莫司与红细胞和血浆蛋白结合,为无药理活性部分。
  • 游离(未结合)血浆他克莫司和细胞内他克莫司仅占全血浓度1%或更少。
  • 他克莫司通过抑制T淋巴细胞内钙调磷酸酶发挥作用,测定淋巴细胞内他克莫司浓度可能更好反映药效。
  • 关于细胞内他克莫司浓度的研究结果矛盾。
  • P-糖蛋白为表达于淋巴细胞的流出转运体,加入其抑制剂可防止细胞分离过程中他克莫司被排出。

关键数值与推荐

  • 全血中>99%的他克莫司与红细胞和血浆蛋白结合,无药理活性。
  • 游离及细胞内他克莫司仅占全血浓度1%或更少。

临床怎么用

  • 当前全血他克莫司浓度监测仍为主要方法,但主要反映无活性部分。
  • 细胞内他克莫司浓度测定在临床常规应用前,需先优化并标准化细胞分离与检测流程。
  • 未来应在 refined 技术基础上评估细胞内他克莫司浓度与排斥风险的相关性。

局限性

  • 细胞内他克莫司浓度研究结果矛盾,尚未确立其与临床结局的明确关联。
  • 细胞分离过程的有效性与标准化关注不足,是当前技术推广的主要障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The measurement of whole blood (WB) concentrations has been the primary method for therapeutic drug monitoring of tacrolimus since its introduction in the field of organ transplantation. However, >99% of tacrolimus measured in WB is bound to erythrocytes and plasma proteins, which are the pharmacologically inactive fractions. The pharmacologically active fractions, the free (or unbound) tacrolimus in plasma and the intracellular tacrolimus, make up 1% or less of the WB concentration. The mechanism of action of tacrolimus is to inhibit the enzyme calcineurin within T lymphocytes and, therefore, measuring the intralymphocytic tacrolimus concentration may better reflect its pharmacodynamic effects and better correlate with clinical outcomes. However, studies on intracellular tacrolimus concentrations have shown conflicting results. In this review, we argue that we need to overcome the analytical limitations of current assays for the measurement of intracellular tacrolimus before moving this technique into the clinical setting. The validity and standardization of the cell isolation process before the measurement of the intracellular tacrolimus concentration is as important as the measurement itself but has received little attention in our view. Recent evidence suggests that the addition of an inhibitor of P-glycoprotein, an efflux transporter expressed on lymphocytes, prevents the expulsion of tacrolimus during the cell isolation process. Refining the technique for the intracellular tacrolimus concentration measurement should be the focus followed by clinical evaluation of its association with rejection risk.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Udomkarnjananun S, Eiamsitrakoon T, de Winter BCM, et al. Should we abandon therapeutic drug monitoring of tacrolimus in whole blood and move to intracellular concentration measurements? Br J Clin Pharmacol. 2023. PMID: 37897055. doi:10.1111/bcp.15946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。